Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 581

1.

Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.

Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, Murphy R, Thompson M, White AC Jr, Wolfe P, McMillan FI, Hanna GJ.

Clin Infect Dis. 2007 Mar 1;44(5):749-54. Epub 2007 Jan 25.

2.

Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.

Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B.

J Antimicrob Chemother. 2007 Aug;60(2):436-9. Epub 2007 Jun 7.

3.

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, Benson C, King KR, Murphy RL, Brun SC.

AIDS. 2004 Mar 26;18(5):775-9.

PMID:
15075512
5.

Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.

King MS, Bernstein BM, Walmsley SL, Sherer R, Feinberg J, Sanne I, Cernohous P, Montaner JS, Brun SC, Sun E.

J Infect Dis. 2004 Jul 15;190(2):280-4. Epub 2004 Jun 11.

6.

Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.

Bisset LR, Cone RW, Huber W, Battegay M, Vernazza PL, Weber R, Grob PJ, Opravil M.

AIDS. 1998 Nov 12;12(16):2115-23.

PMID:
9833852
7.
8.

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, Kessler H.

J Infect Dis. 1998 Jul;178(1):70-9.

9.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
10.

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC Jr, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E.

AIDS. 2001 Jan 5;15(1):F1-9.

PMID:
11192874
11.

Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M.

Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):729-35.

PMID:
16388722
12.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
13.

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, Pumarola T, Gallart T, Miró JM, Gatell JM.

AIDS. 1999 Jul 30;13(11):F79-86.

PMID:
10449278
14.

[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].

Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.

Zhonghua Yi Xue Za Zhi. 2007 Nov 13;87(42):2973-6. Chinese.

PMID:
18261327
15.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E.

J Infect Dis. 2004 Jan 1;189(1):51-60. Epub 2003 Dec 31.

16.

Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler Palacín P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA.

J Antimicrob Chemother. 2008 Jan;61(1):183-90. Epub 2007 Nov 19.

17.

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.

AIDS. 2008 Jan 30;22(3):385-93. doi: 10.1097/QAD.0b013e3282f3f16d.

PMID:
18195565
18.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin C, Burri M, Shen Y, Rode R, Nadal D; Pediatric Infectious Disease Group of Switzerland; Swiss Mother and Child HIV Cohort Study (MoCHiV).

Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

PMID:
18382386
19.

Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.

Thuret I, Michel G, Chambost H, Tamalet C, Giraud P, Brunet C, Perrimond H.

AIDS. 1999 Jan 14;13(1):81-7.

PMID:
10207548
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk